Evidence map›Paper›PMID 35141050›Full record

ArticleMolecular therapy. Nucleic acids2022

Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice.

Shuxian Song, Meghan J Lyle, Misty L Noble-Vranish, Dominic M Min-Tran, James Harrang, Weidong Xiao, Evan C Unger, Carol H Miao

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Non-viralMolecular therapy. Nucleic acids · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Development of Ultrasound Microbubbles and Phase Shift Microbubbles in Theranostics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shuxian SongSeattle Children's Research Institute, Seattle, WA, USA.
Meghan J LyleSeattle Children's Research Institute, Seattle, WA, USA.
Misty L Noble-VranishSeattle Children's Research Institute, Seattle, WA, USA.
Dominic M Min-TranSeattle Children's Research Institute, Seattle, WA, USA.
James HarrangSeattle Children's Research Institute, Seattle, WA, USA.
Weidong XiaoIndiana University, Indianapolis, IN, USA.
Evan C UngerNuvOx Pharma, LLC, Tucson, AZ, USA.
Carol H MiaoSeattle Children's Research Institute, Seattle, WA, USA.
Indiana University – Purdue University Indianapolis · USNuvOx Pharma (United States) · USUniversity of Washington · US

Funding

Temple Project 1: Genetic characterization of factor VIII Inhibitors and glydosylation patternsU54HL142019 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI LI, LEI, MIAO, CAROL H · 2018 to 2022
$6.9M
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia AR01HL151077 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2020 to 2023
$3.2M
Development of highly efficient factor VIII mini-gene therapyR01HL130871 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2016 to 2019
$1.9M
Development of clinically feasible Ultrasound-mediated gene therapy for hemophiliaR01HL128139 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2015 to 2018
$1.9M
NHLBI NIH HHS R01 HL128139NHLBI NIH HHS R01 HL130871NHLBI NIH HHS R01 HL151077NHLBI NIH HHS U54 HL142019
6 · The paper itself

Abstract

Gene therapy offers great promises for a cure of hemophilia A resulting from factor VIII (FVIII) gene deficiency. We have developed and optimized a non-viral ultrasound-mediated gene delivery (UMGD) strategy. UMGD of reporter plasmids targeting mice livers achieved high levels of transgene expression predominantly in hepatocytes. Following UMGD of a plasmid encoding human FVIII driven by a hepatocyte-specific promoter/enhancer (pHP-hF8/N6) into the livers of hemophilia A mice, a partial phenotypic correction was achieved in treated mice. In order to achieve persistent and therapeutic FVIII gene expression, we adopted a plasmid (pHP-hF8-X10) encoding an FVIII variant with significantly increased FVIII secretion. By employing an optimized pulse-train ultrasound condition and immunomodulation, the treated hemophilia A mice achieved 25%-150% of FVIII gene expression on days 1-7 with very mild transient liver damage, as indicated by a small increase of transaminase levels that returned to normal within 3 days. Therapeutic levels of FVIII can be maintained persistently without the generation of inhibitors in mice. These results indicate that UMGD can significantly enhance the efficiency of plasmid DNA transfer into the liver. They also demonstrate the potential of this novel technology to safely and effectively treat hemophilia A.

Indexed as

factor VIIIfactor VIII variantsgene deliveryhemophiliamicrobubblenonviral gene transferpersistent gene expressionultrasoundultrasound mediated gene deliveryUMGD

Identifiers

PMID35141050
PMCPMC8803955
OpenAlexW4206379867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.